![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » C2N Diagnostics Unveils Breakthrough Alzheimer’s Blood Test
C2N Diagnostics Unveils Breakthrough Alzheimer’s Blood Test
C2N Diagnostics announced the planned launch of its new diagnostic blood test, PrecivityAD2, which uses mass spectrometry and a statistical algorithm to detect the two key drivers behind Alzheimer’s disease — tau and amyloid beta proteins.
The test calculates an amyloid probability score to detect whether a patient is positive or negative for brain amyloid plaques, which can cause this form of dementia. The test uses a blood sample instead of PET scans and spinal taps.
The company said clinical studies show that the test is comparable to the current standards at a lower cost and with less discomfort to the patient.
PrecivityAD2 is a new version of the firm’s PrecivityAD, a test that calculates an amyloid beta ratio but does not detect tau.
C2N Diagnostics intends to launch the new test in the first quarter of 2023.
Upcoming Events
-
11Jul
-
18Jul
-
21Oct